Induction of Protection against Porcine Cysticercosis by Vaccination with Recombinant Oncosphere Antigens

Flisser, Ana; Gauci, Charles G.; Zoli, A; Martinez-Ocaña, Joel; Garza-Rodriguez, Adriana; Domínguez-Alpízar, J. L.; Maravilla, Pablo; Rodríguez-Canul, Rossanna; Ávila, Guillermina; Aguilar-Vega, Laura; Kyngdon, Craig T.; Geerts, S.; Lightowlers, Marshall W.

doi:10.1128/iai.72.9.5292-5297.2004

Cited by 162 publications

(162 citation statements)

References 34 publications

Supporting

Mentioning

146

Contrasting

Unclassified

Order By: Relevance

“…Two different T. solium recombinant oncosphere proteins (Tsol18 and Tsol45) have been tested and shown to be highly effective in protecting pigs against cysticercosis [14,15]. Both proteins plus a third, Tsol16, have been identified and cloned by homology to the T. ovis and T. saginata protective antigens [26;27;].…”

Section: Discussionmentioning

confidence: 99%

“…The essential role of pigs as obligatory intermediate hosts presents a possibility of interfering with transmission of both diseases (taeniasis and cysticercosis) through vaccination of pigs. To date, oncosphere antigens are the most effective vaccine candidates in preventing cysticercosis [10][11][12][13][14][15]. We identified two oncosphere protein bands in western blot that were associated with immune protection against cysticercosis in pigs [12].…”

Section: Introductionmentioning

confidence: 97%

See 1 more Smart Citation

Characterization of a novel Taenia solium oncosphere antigen

Mayta

Hancock

Levine

et al. 2007

Molecular and Biochemical Parasitology

View full text Add to dashboard Cite

Infections due to Taenia solium in humans (taeniasis/cysticercosis) remain a complex health problem, particularly in developing countries. We identified two oncosphere proteins that might protect the porcine intermediate host against cysticercosis and therefore help prevent disease in humans. One of these proteins was further identified by two-dimensional gel-electrophoresis and microsequencing. The gene encoding this protective protein was also identified, cloned and characterized. The native 31.5 KD protein Tso31 has four variants at the cDNA level. The longest sequence from which the others seem to derive, encodes a 253 amino acid peptide. The predicted protein has a molecular weight of 25.1 KD, one putative N-glycosylation site, two fibronectin type III domains, and one C terminal transmembrane domain. The gene structure of the protein consists of four exons and three introns. The finding of one gene and four different cDNAs for Tso31 suggests the existence of a possible mechanism of differential splicing in this parasite. The Tso31 protein is exclusive to T. solium oncospheres with a putative protein structure of an extra-cellular receptor-like protein. The Tso31 protein was expressed as a recombinant protein fused to GST and tested in a vaccine to determine its effectiveness in protecting pigs against cysticercosis. Only two pigs out of eight vaccinated were protected and although the total median number of cyst decreased in vaccinated pigs compared to controls this decrease was not statistically significant (P=0.09).

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 97%

Characterization of a novel Taenia solium oncosphere antigen

Mayta

Hancock

Levine

et al. 2007

Molecular and Biochemical Parasitology

View full text Add to dashboard Cite

show abstract

“…El grupo de parasitología veterinaria de la Universidad de Melbourne, Australia, encabezado por el Dr. Marshall Lightowlers, desarrolló una vacuna altamente eficaz para la cisticercosis porcina, probada inicialmente en México, Camerún y Perú a inicios de la primera década del 2000. Esta vacuna, llamada TSOL18, tiene una eficacia superior al 99% y fue desarrollada siguiendo el esquema de vacunas similares contra Taenia ovis y Taenia saginata (30,31) .…”

Section: Control En Camalesunclassified

Epidemiología y control de la cisticercosis en el Perú

Garcı́a¹,

González²,

Rodríguez³

et al. 2010

Rev Peru Med Exp Salud Publica

View full text Add to dashboard Cite

por el Grupo de Trabajo en Cisticercosis en Perú RESUMEN La neurocisticercosis, infección del sistema nervioso humano por el estadio larvario de la Taenia solium, es una causa importante de epilepsia y otras manifestaciones neurológicas en el Perú y en la mayoría de países en desarrollo. Desde 1987, el Grupo de Trabajo en Cisticercosis en Perú ha desarrollado una serie de estudios epidemiológicos que han llevado a estimar el impacto y entender la transmisión de la Taenia solium, y que posteriormente se aplicaron al diseño y ejecución de un programa de control en Tumbes, en la costa norte del país. En este artículo se revisan los principales hallazgos epidemiológicos, así como las líneas generales del programa de eliminación y las herramientas utilizadas. Los avances en el control de la teniasis/cisticercosis en nuestro país abren el camino hacia su eliminación y eventual erradicación.Palabras clave: Cisticercosis; Taenia solium; Epidemiología; Control de enfermedades transmisibles; Perú (fuente: DeCS BIREME). EPIDEMIOLOGY AND CONTROL OF CYSTICERCOSIS IN PERU ABSTRACTNeurocysticercosis, the infection of the human central nervous system by the larval stage of the cestode Taenia solium, is an important cause of epilepsy and other neurological manifestations in Peru and most developing countries. Since 1987, the Cysticercosis Working Group in Peru has performed a series of epidemiological studies which led to estimate the impact and to better understand the transmission of Taenia solium. This information was later applied to the design and execution of a control program in Tumbes, in the Northern Coast of Peru. This paper reviews the main epidemiological findings, as well as the conceptual framework of the elimination program and the tools used. Advances in the control of taeniasis/cysticercosis in our country open the road towards its elimination and potential eradication.

show abstract

“…TSOL18 has been assessed in five separate pig vaccine trials, under experimental conditions conducted by four independent groups of scientists in four different countries. In the challenge trials, TSOL18 consistently provided vaccinated pigs with nearly complete protection against T. solium infection, achieving 100% and 99.5% protection in Mexico, 13 99.9% in Peru, 15 100% in Cameroon 13 and 99.3% in Honduras. 16 In addition, the TSOL18 antigen was shown to completely eliminate transmission of T. solium to pigs in a vaccine field trial conducted in the Mayo-Danay district of north Cameroon, 17 a region previously identified as having a high prevalence of T. solium.…”

mentioning

confidence: 99%

“…12 Each of these antigens has been shown to induce near complete protection in vaccinated pigs challenged with T. solium under experimental conditions. [13][14][15] The TSOL18 antigen has shown the greatest potential. TSOL18 has been assessed in five separate pig vaccine trials, under experimental conditions conducted by four independent groups of scientists in four different countries.…”

mentioning

confidence: 99%